Paige AI vs Regard AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Paige AI employs 100-500 people, while Regard AI has 50-200 employees.

Paige AI has raised more in total funding at $125M, compared to Regard AI's $30M — a gap of $95M.

Paige AI holds the higher Awaira Score at 65/100, compared to Regard AI's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

Paige AI was founded by Leo Grady in 2018. Regard AI's founder information is not currently available in our database.

Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.

Regard AI was founded first in 2017, giving it 1 year of additional market experience. Paige AI was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Paige AI has approximately 100-500 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Paige AI and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.